Metropolis Healthcare Exceeds Growth Targets, Sets Ambitious Margin Goals

Metropolis Healthcare announced it achieved 13.7% organic revenue growth in fiscal year 2026, surpassing its own guidance. The company also reported a significant turnaround for its acquisition, Core Diagnostics, which reached high-single-digit EBITDA margins by the fourth quarter of FY26.

Key Financial Highlights

Metropolis Healthcare's latest results for Q4 and FY26 reveal strong performance. The company's strategic emphasis on integrating acquisitions and expanding its network has paid off. Core Diagnostics, previously operating at negative margins, has now achieved high-single-digit EBITDA margins in Q4 FY26. This expansion has seen the addition of 490 new centers in FY26, bringing the total network to over 5,000 collection centers and 212 laboratories.

Driving Future Growth

This performance demonstrates Metropolis Healthcare's successful execution of its growth strategy. The turnaround at Core Diagnostics is a notable achievement. A growing network, coupled with increasing revenue from self-referrals (40%) and digital channels (25%), positions the company for sustained growth. Management's confidence is reflected in their targets for revenue CAGR of 14-15% and group EBITDA margins of 27-28% over the next three years.

Strategic Foundation

Metropolis Healthcare has actively worked to expand its presence and solidify its market position in the diagnostic services industry. The company has prioritized organic growth while carefully considering acquisition opportunities. The integration of Core Diagnostics was a key step to improve market reach and profitability.

What Investors Can Expect

Following its FY26 results, Metropolis Healthcare is signaling a continued commitment to profitable expansion. The company aims for an additional EBITDA margin improvement of 125 to 150 basis points in FY27. Investors can anticipate further network expansion and a greater emphasis on specialty services, such as genomics, to enhance margins. The introduction of 100 'mini hubs' is also planned.

Potential Challenges Ahead

Management noted that finding suitable acquisition assets that meet their standards remains a challenge. Furthermore, aggressive network expansion and investments in new genomic machinery are expected to lead to a notable increase in depreciation costs.

Market Position

Metropolis Healthcare's organic growth rate of 13.7% in FY26 stands out. While specific peer margins were not detailed, the company's target of 27-28% EBITDA margin suggests it is aiming for a leading position in profitability within the diagnostic sector. Growth in Tier 3 cities, at 26-30%, is significantly higher than in Tier 1 cities, which are growing at approximately 11%.

Key Performance Indicators

• FY26 Organic Revenue Growth: 13.7%
• FY26 Network Expansion: Added 490 centers, total >5,000 centers
• Q4 FY26 Core Diagnostics EBITDA Margin: High-single-digit (turnaround)
• Digital Revenue Contribution: 25%
• Self-Referral (D2C) Revenue Contribution: 40%
• Target FY27 EBITDA Margin Improvement: 125-150 bps
• Target 3-Year Revenue CAGR: 14-15%
• Target 3-Year Group EBITDA Margin: 27-28%
• FY27 Volume Growth Estimate: 8-9%

Looking Ahead

Investors will be watching Metropolis Healthcare's progress toward its 27-28% EBITDA margin goal and the rollout of its 'mini hubs'. The company's ability to drive volume growth while managing increased depreciation will be key factors to monitor.